CYP2D6 and breast carcinoma: We also found CYP2D6*4 carriers had 1.76- and 3.7-fold worsening of overall and breast cancer-specific survivals, respectively, while *4 homozygotes had a striking 11-fold increase in breast cancer-specific mortality.